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The steroid metabolome in women with premenstrual
dysphoric disorder during GnRH agonist-induced ovarian
suppression: effects of estradiol and progesterone addback
TV Nguyen1,2,10, JM Reuter1,10, NW Gaikwad3,10, DM Rotroff4,5, HR Kucera3, A Motsinger-Reif4,5, CP Smith4,5, LK Nieman6, DR Rubinow7,
R Kaddurah-Daouk8,9 and PJ Schmidt1
Clinical evidence suggests that symptoms in premenstrual dysphoric disorder (PMDD) reflect abnormal responsivity to ovarian
steroids. This differential steroid sensitivity could be underpinned by abnormal processing of the steroid signal. We used a
pharmacometabolomics approach in women with prospectively confirmed PMDD (n= 15) and controls without menstrual cycle-
related affective symptoms (n= 15). All were medication-free with normal menstrual cycle lengths. Notably, women with PMDD
were required to show hormone sensitivity in an ovarian suppression protocol. Ovarian suppression was induced for 6 months with
gonadotropin-releasing hormone (GnRH)-agonist (Lupron); after 3 months all were randomized to 4 weeks of estradiol (E2) or
progesterone (P4). After a 2-week washout, a crossover was performed. Liquid chromatography/tandem mass spectrometry
measured 49 steroid metabolites in serum. Values were excluded if 440% were below the limit of detectability (n= 21). Analyses
were performed with Wilcoxon rank-sum tests using false-discovery rate (qo0.2) for multiple comparisons. PMDD and controls had
similar basal levels of metabolites during Lupron and P4-derived neurosteroids during Lupron or E2/P4 conditions. Both groups had
significant increases in several steroid metabolites compared with the Lupron alone condition after treatment with E2 (that is,
estrone-SO4 (q= 0.039 and q= 0.002, respectively) and estradiol-3-SO4 (q= 0.166 and q= 0.001, respectively)) and after treatment
with P4 (that is, allopregnanolone (q= 0.001 for both PMDD and controls), pregnanediol (q= 0.077 and q= 0.030, respectively) and
cortexone (q= 0.118 and q= 0.157, respectively). Only sulfated steroid metabolites showed significant diagnosis-related differences.
During Lupron plus E2 treatment, women with PMDD had a significantly attenuated increase in E2-3-sulfate (q= 0.035) compared
with control women, and during Lupron plus P4 treatment a decrease in DHEA-sulfate (q= 0.07) compared with an increase in
controls. Significant effects of E2 addback compared with Lupron were observed in women with PMDD who had significant
decreases in DHEA-sulfate (q= 0.065) and pregnenolone sulfate (q= 0.076), whereas controls had nonsignificant increases (however,
these differences did not meet statistical significance for a between diagnosis effect). Alterations of sulfotransferase activity could
contribute to the differential steroid sensitivity in PMDD. Importantly, no differences in the formation of P4-derived neurosteroids
were observed in this otherwise highly selected sample of women studied under controlled hormone exposures.
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INTRODUCTION
Premenstrual dysphoric disorder (PMDD) is a clinically distinct
affective disorder characterized by recurrent and distressing mood
and behavioral symptoms during the luteal phase of the
menstrual cycle that remit within a few days from the onset of
menses.1–3 Levels of circulating ovarian steroids, estradiol (E2) and
progesterone (P4) and hypothalamic–pituitary–ovarian axis func-
tion are normal.4 However, when ovarian steroid secretion is
suppressed by gonadotropin-releasing hormone (GnRH) receptor
agonists, women with PMDD experience remission of symptoms,
which recur when physiologic doses of E2/P4 are added back. In
contrast, asymptomatic controls undergoing identical hormone
manipulations experience no changes in mood.5 Thus, in women
with PMDD, clinical evidence suggests that symptoms are
triggered by a differential central nervous system (CNS) response
to physiologically normal changes in E2/P4. Furthermore, imaging
studies identified brain regions modulated by E2/P4 (or their
neuroactive metabolites), some of which respond differently in
women with PMDD despite similar exposures to E2/P4, including
the amygdala, striatum, medial orbitofrontal cortex, anterior
cingulate cortex and prefrontal cortex.6–15 One candidate
hormone that could mediate the differential regulation of brain
circuitry in PMDD, and the triggering of symptoms by at least
progesterone, is the ring A-reduced neurosteroid allopregnano-
lone. Despite the absence of consistent demonstrations of
abnormal peripheral levels of allopregnanolone in PMDD
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compared with control women,16–22 there is preliminary evidence
to support the hypothesis that changes in the production of or
alterations in the metabolism of allopregnanolone from proges-
terone could serve as an 'affective switch' in susceptible women
(reviewed in Schiller.16,23 These observations not only suggest that
the symptoms of PMDD are accompanied by ovarian steroid-
related alterations in the activity of neuronal circuits underlying
reward, social cognition and affective states,4 but also that ovarian
steroids could be processed differently in women with PMDD in
peripheral tissues and potentially in the CNS (or alternatively
reflect differential signal transduction within the CNS).
Abnormalities in steroid metabolism are present in several
conditions, including prostate cancer, breast cancer and polycystic
ovary syndrome,24–27 and metabolomics platforms have been
employed to investigate biochemical systems (for example, lipids
and neurotransmitter metabolites) in metabolic and psychiatric
conditions.28–30
We hypothesized that women with PMDD would display altered
steroid metabolic profiles/signatures compared with asympto-
matic control women during controlled and standardized
exposures to ovarian steroids. To test this, we used a steroid-
based metabolomics platform to compare asymptomatic controls
and women with PMDD in whom symptom remission and
recurrence (that is, E2/P4 sensitivity) were confirmed by ovarian
steroid manipulation.5 The main goal of this study was to examine
the potential differences in the metabolic processing of standar-
dized doses of ovarian steroids in women with PMDD and
controls. Metabolomics tools enable identification and quantifica-
tion of tens to thousands of compounds that represent changes in
biochemical pathways31,32 in response to treatment. Metabolo-
mics strategies have also mapped global biochemical changes in
depression, characterized the effects of selective serotonergic re-
uptake inhibitors on metabolic pathways and defined several
pathways implicated in individual variation in response to these
medications.33–35
MATERIALS AND METHODS
Participant selection
We studied 15 women with PMDD aged 23–48 years. All were medication-
free, with regular menstrual cycles (range, 21–35 days), not medically ill
and not pregnant. Women with PMDD were self-referred in response to
newspaper advertisements or were referred by their physician. Before
study entry PMDD was confirmed in these women based on criteria
outlined in the American Psychiatric Association’s Diagnostic and Statistical
Manual of Mental Disorders, fourth edition (DSM-IV).36 Women completed
3 months of prospective daily ratings using a four-item 100-mm visual-
analog scale that confirmed the timing and severity of their self-reported
menstrually related mood symptoms (irritability, sadness, anxiety and
mood swings) as described previously.5,37 The mean score of at least one
negative mood symptoms was at least 30% higher (relative to the range of
the scale used by each woman) in the week before menstruation
compared with the week after the cessation of menstruation in at least
two of the three cycles. Functional impairment was characterized as a daily
rating form (DRF)38 score of 2 (minimal) or higher on one of 4 questions
related to functional impairment (that is, stayed at home or avoided social
activities, had conflicts or problems with people, symptoms interfered with
relationships at work or home or symptoms interfered with work
productivity) in at least 3 days out of 7 days pre-menses. Finally, DRF
ratings and the results of both a semi-structured interview and a self-report
questionnaire (that is, the Menstrual Screening Questionnaire and the
Menstrual Assessment Form, respectively) confirmed that all women met
the required number of symptoms specified in the DSM. Women with
significant negative mood symptoms (on the DRF) during the follicular
phase of the menstrual cycle were excluded. Thus, the diagnostic criteria
for PMDD were augmented by the severity criterion of a 30% or greater
increase in the mean negative mood during the week before menses
compared with the week after menses—a more stringent criterion than
that of DSM-IV or V.1,36
We also recruited a group of 15 control women, none of whom had
premenstrual mood symptoms using the same daily rating scales during a
2-month baseline period.
The women with PMDD had no current Axis I psychiatric diagnosis
within the past 2 years per Structured Clinical Interview for DSM-IV
(SCID),39 while controls had neither current nor past Axis I diagnoses (also
confirmed by SCID).
This study was approved by the Central Neuroscience Institutional
Review Board within the NIMH IRP. All women provided written informed
consent, and all received payment for participation according to the NIH
intramural guidelines.
Hormone manipulation protocol
Participants received six monthly injections of the GnRH agonist leuprolide
acetate, Lupron (3.75 mg intramuscularly). Plasma follicle stimulating
hormone (FSH), luteinizing hormone (LH), estradiol and progesterone
levels were measured at study visits every 2 weeks to confirm adequate
gonadal suppression. Following 3 months of Lupron alone, participants
were randomly assigned in a double-blind, crossover manner to receive
either E2 (100 mcg daily by skin patch, Noven Pharmaceuticals Jersey City,
NJ, USA, Watson Pharmaceuticals, Parsippany, NJ, USA) or P4 (200 mg
vaginal suppository twice daily, Upsher-Smith Laboratories; NIH Pharmacy,
Bethesda, MD, USA) replacement lasting for 5 weeks (with a 2-week
washout between hormone administration periods) while continuing to
receive Lupron injections (Figure 1). All women used a patch and a
suppository each day during the hormonal addback to maintain the
patency of the double-blind. This standardized the exposures to
physiologic levels of ovarian steroids to avoid the confound of varying
levels of estradiol and progesterone across the normal menstrual cycle. All
women used the appropriate placebo patch or suppository daily during
the 12-week addback.
Time
(weeks)
42210
OR
Estradiol 0.1 mg/d
Leuprolide Acetate (3.75 mg IM QM)
Progesterone 200 mg BID 
Blood samples obtained
Figure 1. Protocol schematic for clinical hormone suppression/
addback protocol. Between 2 and 5 days after onset of menses,
women with PMDD and control women received six monthly
intramuscular injections of 3.75-mg leuprolide (Lupron), which after
an initial stimulation suppresses ovarian function. Clinic visits
occurred every 2 weeks. Plasma FSH, LH, estradiol and progesterone
levels were measured at each visit to confirm ovarian suppression.
Following 3 months of leuprolide alone, all participants (while
continuing to receive monthly leuprolide injections for another
3 months) were randomly assigned in a double-blind, crossover
manner to receive either E2 (100 mg daily by skin patch) or P4
(200 mg vaginal suppository twice daily) replacement lasting for
5 weeks each (with a 2-week washout between hormone admin-
istration periods). All women used a patch and a suppository each
day during the hormonal addback to maintain the patency of the
double-blind. After 4 weeks of E2 all women received 1 week of P4
to induce menses (at the end of a 4-week E2 exposure). Significant
recurrence of PMDD symptoms was defined by a weekly average
DRF score of greater than three (moderate severity) in irritability,
anxiety or sadness.40,41 Controls were defined by an absence of
affective symptoms throughout the 6-month hormone-manipula-
tion protocol (that is, no weekly average score42). DRF, daily rating
form; E2, estradiol; P4, progesterone; PMDD, premenstrual dysphoric
disorder.
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Symptom ratings and criteria for response
Women completed a modified DRF,38 daily to measure symptom severity
during the 6-month hormone-manipulation study. A significant recurrence
of PMDD symptoms was defined by a weekly average DRF score of greater
than three (moderate severity) in irritability, anxiety or sadness.40,41
Asymptomatic controls had no affective symptoms during the 6 months
(that is, no weekly average score ⩾ 2). At each clinic visit, all women
completed the Rating for Premenstrual Tension self-ratings,42 a self-report
rating that measures mood, behavior and physical symptoms on a 36-point
scale, with scores ⩾ 10 consistent with PMDD symptoms.
Blood samples
Serum was obtained and stored at − 80 °C for metabolomics analysis after
at least 8 weeks of GnRH agonist-induced ovarian suppression (hypogo-
nadal state and PMDD symptoms in remission), after 2–3 weeks of estradiol
and after 2–3 weeks of progesterone addback (when symptoms recur in
PMDD but not in control women).
Selection of steroid metabolites
We tested 49 metabolites with a focus on estradiol, progesterone and
pregnenolone biosynthesis (see Table 1 and Supplementary Table S1, and
the Kyoto Encyclopedia of Genes and Genomes: http://www.genome.jp/
kegg/pathway.html). We selected direct precursors or metabolites of
estradiol (estrone, estriol and so on), progesterone (pregnenolone,
pregnenolone sulfate (3b-hydroxy-5-pregnen-20-one-3-SO4), allopregna-
nolone (3a-hydroxy-5a-pregnan-20-one)) and testosterone (androstene-
dione, dehydroepiandrosterone (DHEA)) and metabolites with neuroactive
potential.43,44 Of particular interest were steroids with direct actions at the
GABAA receptor, including pregnenolone and DHEA (direct or indirect
positive modulators) or their sulfated metabolites, pregnenolone sulfate
and dehydroepiandrosterone-SO4 (DHEAS; direct or indirect negative
modulators).43–45 The sulfation of several neuroactive steroids converts
agonist actions at GABAA receptors to antagonist effects, whereas removal
of the sulfate group has the opposite effect.43–45
Finally, we measured levels of cortexolone, cortisol, corticosterone and
cortexone to evaluate possible alternate pathways of steroid metabolism
(analogous to the diversion of cholesterol precursors from corticosteroids
toward sex steroid synthesis in congenital adrenal hyperplasia46,47).
Sample preparation and analysis
Serum samples were extracted and subjected to ultraperformance liquid
chromatography tandem mass spectrometry analysis for measurement
of neurosteroids in serum samples as described previously27 (see
Supplementary Methods for detail).
Statistical analyses
Demographic and clinical differences across diagnostic groups. To compare
demographic and clinical characteristics of women with PMDD and control
women (that is, age, body mass index (BMI), days of exposure to Lupron, E2
and P4, storage times,48,49 parity and race), we used Student’s t-tests and
χ2-tests (or Fisher’s exact test when appropriate), with a significance
threshold of Po0.05, uncorrected for multiple comparisons. We employed
analysis of variance with repeated measures (ANOVA-R) to examine
potential differences in serum levels of estradiol and progesterone with
diagnosis (that is, PMDD and control women) as a between-group factor
and hormone condition (that is, Lupron alone, estradiol addback and
progesterone addback) as the within-subject factor. Finally, we also used
ANOVA-Rs to examine differences in symptom severity across hormone
conditions or between diagnoses.
Metabolomic differences across diagnostic groups. We did not use
metabolite data with greater than 40% of values below the individual
assay’s limits of detectability (LOD) in any of the two diagnostic groups or
in any of the three hormone conditions. These non-detectable metabolites
were distributed across both diagnostic groups and all hormone
conditions. Thus, metabolites meeting this criterion in any hormone
condition were not included in analyses examining the change in the
metabolite level from Lupron to E2 or Lupron to P4, or the differences
across diagnoses in basal metabolite levels within each hormone
condition.
To analyze differences in metabolite concentrations between the
women with PMDD and control women, we used the open-source
statistical software, R (R Foundation for Statistical Computing, Vienna,
Austria; ISBN 3-900051-07-0 http://www.R-project.org/).
Women were first stratified by diagnostic group (PMDD and controls),
and within each diagnostic group we tested for significant metabolite
differences between each of the three hormone conditions using a non-
parametric, paired Wilcoxon rank-sum test. Subsequently, changes in
metabolite levels between PMDD and control women (that is, diagnosis-
related differences in the 'delta' metabolite level) from Lupron to E2 and
from Lupron to P4 were tested using an unpaired Wilcoxon rank-sum test.
All results were corrected for multiple comparisons using a false-discovery
rate approach (qo0.2).50,51
RESULTS
Sample characteristics
Demographics and clinical characteristics of women with PMDD
and control women are listed in Table 2. Women with PMDD were
significantly older and had higher BMI compared with control
women (both comparisons Po0.05). There were no between-
group differences in racial distribution, parity, the durations of
exposure to Lupron, E2 or P4 prior to obtaining the serum
samples, storage times or race (P40.05 for all comparisons). Only
one woman with PMDD had a past major depression, the rest had
no past Axis I psychiatric illness. Ten women with PMDD
experienced symptom recurrence only after exposure to the P4,
four women only after E2 exposure and one under both P4 and E2
exposures. There was a significant diagnosis-by-hormone interac-
tion in severity scores on the Premenstrual Tension-rater (P= 0.02)
reflecting significantly greater symptom severity in PMDD during
addback compared with Lupron alone and compared with control
women during addback of E2 or P4 treatment.
Table 1. Restricted neurosteroid panel
Androgens Estrogens Progestogens Corticosteroids
Dehydroepiandrosterone Estrone 9-Dehydroprogesterone Cortexolone
DHEAS Estradiol Progesterone Cortisol
Dehydroepiandrosterone glucuronide Estradiol-3-SO4 3a-Hydroxy-5a-pregnan-20-one (allopregnanolone) Cortexone
Androstenedione Estrone-3-SO4 17a,20a-Dihydroxyprogesterone Corticosterone
Testosterone Estrone-3-glucuronide 3b-Hydroxy-5-pregnen-20-one-3-SO4 (pregnenolone sulfate)
2-hydroxyestrone Pregnanediol
Abbreviations: DHEAS, dehydroepiandrosterone-SO4; LOD, limit of detectability; SO4, sulfate group. This table shows the restricted neurosteroid panel, which
outlines the steroid metabolites meeting the threshold for inclusion (o40% of values below LOD) in all of the three hormone conditions (total 21 metabolites,
out of 49 metabolites tested). The complete neurosteroid panel (see Supplementary Table S1) included 49 selected steroid hormones that are direct precursors
or metabolites of testosterone, estradiol and progesterone, as well as their sulfated derivatives. We also measured corticosteroid levels, in order to rule out
decreased activity in the synthetic enzymes for sex steroids leading to a diversion of cholesterol precursors toward corticosteroid synthesis.
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Levels of serum estradiol and progesterone during Lupron alone
and after each hormonal addback condition
There were no significant effects of diagnosis or a diagnosis-by-
hormone condition interaction for levels of either estradiol or
progesterone. All women (PMDD and control) treated with E2
showed significant increases in serum estradiol after E2 treatment
compared with Lupron, and significant increases in serum
progesterone levels after P4 treatment (Table 3).
Comparisons of basal steroid metabolite levels between women
with PMDD and controls
There were no differences in absolute steroid metabolite levels
between women with PMDD and controls in the Lupron, E2 or P4
addback conditions (Table 3).
Differences in steroid metabolite levels from Lupron to E2 or
Lupron to P4 treatment
Changes in steroid metabolite levels observed in both PMDD and
Controls. Compared with the Lupron condition, treatment with
E2 (Table 4) resulted in significant increases, in both PMDD and
control women, in levels of estrone-SO4 and estradiol-3-SO4 levels
(Table 4).
Compared with the Lupron condition, replacement of P4
(Table 5) resulted in significant increases, in both PMDD and
control women, in serum levels of allopregnanolone and
pregnanediol. Serum levels of cortexone also were significantly
increased in both groups.
Changes in steroid metabolite levels that differed between PMDD
and Controls. Only estradiol-3-SO4 levels showed a significant
diagnostic difference between PMDD and control women after E2
treatment compared with Lupron (Table 4). Women with PMDD
had a significantly attenuated (that is, blunted) increase in
estradiol-3-sulfate after E2 compared with control women. Other
E2-related changes in steroid metabolite levels did not differ
between PMDD and control women. Despite the absence of other
significant between-group differences, significant within-group
differences between Lupron and hormone-replaced were
observed in one group but not in the other. Within-group
differences in E2-treated women with PMDD included significant
decreases in estrone, pregnenolone sulfate (3b-hydroxy-5-preg-
nen-20-one-3-SO4), DHEAS and DHEA levels, compared with no
significant change, or a trend toward increased levels of these
metabolites in controls (Table 4).
Only DHEAS levels showed a significant diagnosis-related
difference between PMDD and control women after P4 treatment
(Table 5), with a decrease in serum levels in PMDD and an increase
in controls. Notably, none of the four progesterone-related
neurosteroid metabolites successfully measured (9-dehydropro-
gesterone, 3a-hydroxy-5a-pregnan-20-one (allopregnanolone),
17a, 20a-dihydroxyprogesterone and pregnanediol) showed sig-
nificant diagnostic differences after P4. In particular, the magni-
tude of the increases in allopregnanolone levels was almost
identical in PMDD and controls (Table 5).
Despite the absence of other significant between-group
differences, significant within-group differences between Lupron
and hormone-replaced conditions were observed in one group
but not in the other. Estradiol-3-SO4 levels and 2-hydroxyestrone
decreased significantly in P4-treated women with PMDD
but not in controls. The significant increases in 17a, 20a-
dihydroxyprogesterone and androstenedione levels observed in
control women were not seen in women with PMDD. Finally, only
women with PMDD showed a significant increase in cortexolone
levels (Table 5).
DISCUSSION
We examined the hypothesis that altered metabolic processing of
ovarian steroids after E2/P4 exposure would distinguish women
with PMDD from matched, asymptomatic controls. The women
with PMDD met clinical criteria for PMDD and, of particular
relevance, were also confirmed to be behaviorally sensitive to E2/
P4.5 Controls lacked any significant menstrual cycle or hormone-
Table 2. Demographics and clinical characteristics of women with
PMDD and control women
Control PMDD
Age (years), mean (s.d.)* 32.9 (8.1) 39.1 (7.3)
BMI (kg/m2), mean (s.d.)* 24.2 (3.5) 27.9 (5.6)
Lupron exposure (days), mean (s.d.) 68.9 (4.0) 71.5 (4.6)
Estradiol exposure (days), mean (s.d.) 20.5 (4.2) 21.8 (6.7)
Progesterone exposure (days), mean (s.d.) 21.9 (4.7) 19.9 (4.1)
Storage times (years) 5.7 (1.9) 6.2 (2.4)
Race (numbers of women)
White 7 5
Black 3 8
Hispanic 4 1
Asian 0 1
Other 1 0
Parity
Parity= 0 9 5
Parity= 1–5 6 10
Past Axis I Psychiatric Illness# (numbers of
women)
0 1
Symptom trigger (numbers of women)*
Progesterone 0 10
Estradiol 0 4
Both 0 1
PMDD symptom severity (Steiner–Carroll scale: self-report)*; mean (s.d.)
Lupron 0.6 (1.1) 1.8 (1.6)
E2 0.1 (0.3) 2.8 (3.1)
P4 0.3 (0.8) 6.1 (7.1)
Abbreviations: ANOVA-R, analysis of variance with repeated measures; BMI,
body mass index; E2, estradiol; P4, progesterone; PMDD, premenstrual
dysphoric disorder. Demographics and clinical information of the sample
are shown in this table. Women with PMDD were significantly older, had
higher BMI and showed significant differences in PMDD symptom severity
compared with controls under all hormone conditions, as well as across
hormone conditions (significant comparisons indicated with an asterisk*,
Po0.05). One woman with PMDD had a past major depression (indicated
with a pound sign#). There were no between-group differences in the
durations of exposure to Lupron, E2 or P4 prior to obtaining the serum
samples, storage times, parity or race (P40.05 for all comparisons). Ten
women with PMDD experienced PMDD symptom recurrence only after
exposure to the P4, 4 women only after E2 exposure only and 1 after both
P4 and E2 exposures. There was a significant diagnosis-by-hormone
interaction in severity scores on the Premenstrual Tension-rater (F2, 56= 4.1,
P= 0.02) reflecting significantly greater symptom severity in PMDD during
addback compared with Lupron alone and compared with control women
during addback of E2 or P4 treatment. ANOVA-R showed no significant
effects of diagnosis (PMDD versus control women) or a diagnosis-by-
hormone condition interaction between diagnosis and hormone condition
for serum levels of either E2 (diagnosis: F1,28= 1.3, P= 0.3; diagnosis-by-
hormone interaction: F2,56= 0.5, P= 0.6) or P4 (diagnosis: F1,28= 0.03,
P= 0.9; diagnosis-by-hormone interaction: F2,56= 0.04, P= 0.9). As outlined
in Tables 3–5, all women (PMDD and control) treated with E2, showed a
significant increase in estradiol with E2 treatment (PMDD: median change
(Median)= 72 pg/ml; q= 0.056; control: Median= 61 pg/ml; q= 0.014), and
a significant increase in progesterone with P4 treatment (PMDD:
Median= 7850 pg/mL; q= 0.001; control: Median= 8530 pg/ml; q= 0.001),
relative to the Lupron condition.
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related behavioral symptoms. Both groups received identical
hormone manipulations to standardize exposures. We used a
targeted metabolomics platform to detect differences in steroid
metabolites in these highly selected clinical phenotypes exposed
to identical doses of E2 and P4 while receiving Lupron.
Despite several studies reporting abnormal levels of P4-derived
neurosteroids in PMDD, our analysis revealed few significant
differences between women with PMDD and controls. Notably,
serum levels of the ring A-derived neurosteroid metabolites of P4
were virtually identical in the groups during all hormonal
conditions. These similar serum levels also suggest that a larger
sample size would be unlikely to reveal significant differences.
These findings contrast with several,16,19–22 but not all, naturalistic
studies across the menstrual cycle17,18 and suggest that basal
Table 3. Serum levels of steroid metabolites (pg ml− 1) in PMDD (n= 15) and controls (n= 15) during three hormone conditions—mean (s.d.)
Treatment; group Lupron alone Estradiol Progesterone
NC PMD NC PMD NC PMD
DHEA 1597.5 (2197.5) 1379.5 (1104.3) 1389.1 (1144.9) 815.8 (774.2) 1947.9 (1766.4) 1127.3 (666.0)
DHEAS 977 766.1
(432 417.6)
765 185.6
(485 557.4)
1 101 474.9
(800 163.7)
511 647.2
(321 591.3)
1 231 969.7
(723 437.8)
553 833.9
(339 282.8)
DHEA-Glu 42 015.6
(16 337.3)
34 679.2
(24 736.1)
47 252.7
(25 905.6)
24 304.7
(22 416.4)
47 073.3
(24 028.9)
28 650.9
(21 361.5)
9-Dehydroprogesterone 2535.9 (2141.0) 2732.3 (2133.7) 2052.9 (1507.0) 1570.8 (1588.6) 2288.0 (1273.9) 1748.0 (1297.8)
7a-Hydroxyandrostenediol 1912.3 (1878.5) 2858.8 (6265.4) NA NA 1163.7 (1025.7) 1730.6 (2602.7)
Progesterone 67.9 (112.3) 56.7 (100.0) 38.6 (32.0) 64.0 (54.1) 8409.2 (3052.7) 8202.8 (3035.3)
Cortexolone 79.8 (123.9) 105.4 (93.9) 65.6 (82.7) 163.9 (205.7) 86.8 (117.7) 171.7 (142.5)
Cortisol 12 000.2
(10 545.0)
17 695.5
(11 174.2)
11 048.2
(10 547.3)
14 754.7
(12 930.9)
18 922.8
(13 818.5)
21 248.8
(16 876.5)
Cortexone 18.3 (25.9) 31.6 (19.1) 19.9 (22.5) 28.8 (31.0) 49.9 (45.1) 68.3 (51.1)
Corticosterone 614.9 (766.8) 615.5 (668.8) 423.3 (634.5) 657.6 (1170.6) 504.7 (376.2) 911.9 (1390.9)
Androstenedione 383.0 (205.1) 406.1 (264.2) 431.0 (249.8) 343.5 (345.7) 518.3 (253.0) 314.0 (265.5)
Testosterone 110.2 (90.8) 94.8 (85.9) 117.6 (145.7) 67.1 (63.7) 88.6 (69.7) 69.8 (82.2)
Estrone 333.4 (301.8) 405.0 (505.6) 438.6 (678.4) 219.0 (118.1) 264.3 (253.9) 305.4 (180.8)
Estradiol 67.4 (82.3) 65.4 (65.6) 156.1 (90.3) 282.2 (567.5) 35.8 (44.8) 86.5 (134.6)
Estradiol-3-SO4 39.2 (23.9) 70.2 (52.1) 179.1 (82.0) 118.7 (94.7) 37.1 (20.5) 46.4 (29.2)
Estrone-SO4 333.8 (118.2) 502.4 (295.6) 2116.6 (1378.0) 1542.1 (1347.9) 349.5 (155.6) 496.9 (375.4)
Estradiol-3-Glu 54.6 (126.9) 31.4 (35.0) 40.3 (44.9) 23.0 (33.1) NA NA
Estrone-3-Glu 835.9 (368.6) 1361.7 (780.6) 1103.4 (551.6) 1201.6 (885.4) 829.4 (506.9) 1050.2 (469.2)
2-Hydroxyestrone 96.0 (150.6) 72.4 (90.8) 233.8 (646.8) 49.6 (49.1) 68.8 (90.3) 46.5 (42.2)
2-Hydroxyestradiol NA NA NA NA NA NA
2-Methoxy-3 OH-estrone NA NA NA NA NA NA
6b-Hyroxyestradiol NA NA NA NA NA NA
16a-Hydroxyestrone NA NA NA NA NA NA
Estriol NA NA NA NA NA NA
3a-Hydroxy-5a-pregnan-20-one 425.8 (163.6) 367.9 (224.2) 370.4 (134.5) 366.3 (138.3) 744.2 (187.7) 686.1 (268.8)
5a-Dihydroprogesterone NA NA NA NA NA NA
Allopregnanediol NA NA NA NA NA NA
11a-Hydroxy-4-pregnene-3,20-
dione
NA NA NA NA NA NA
11b-Hydroxy-4-pregnene-3,20-
dione
NA NA NA NA NA NA
17-Hydroxypregnenolone NA NA NA NA NA NA
17-Hydroxyprogesterone NA NA NA NA NA NA
21-Hydroxypregnanolone 712.2 (715.2) 516.4 (510.6) NA NA NA NA
21-Hydroxypregnenolone NA NA NA NA NA NA
7a-Hydroxypregnenolone NA NA NA NA NA NA
20a-Hydroxy-5a-pregnan-3-one NA NA NA NA NA NA
20a-Dihydroprogesterone NA NA NA NA NA NA
17a,20a-Dihydroxyprogesterone 90.6 (58.7) 93.8 (65.1) 83.5 (71.5) 73.1 (72.6) 144.5 (67.6) 103.1 (57.9)
3b-Hydroxy-5-pregnen-20-one-3-
SO4
17 038.1
(12 188.9)
20 008.5
(12 422.2)
17 864.9
(19 268.8)
12 428.5
(11 518.0)
24 646.4
(18 675.7)
21 174.9
(12 905.6)
Eltanolone (pregnanolone) NA NA NA NA NA NA
Pregnanediol 72.2 (129.4) 111.4 (171.2) NA NA 503.5 (400.3) 418.7 (318.1)
5b-Dihydroprogesterone NA NA NA NA NA NA
5a-Dihydrotestosterone NA NA NA NA NA NA
17b-Dihydroandrosterone NA NA NA NA NA NA
17b-DihydroEPIandrosterone NA NA NA NA NA NA
7a-Hydroxytestosterone NA NA NA NA NA NA
7a-Hydroxyandrostenedione 190.3 (194.1) 284.1 (244.1) NA NA 209.2 (322.9) 363.5 (531.6)
27-Hydroxycholesterol NA NA NA NA NA NA
24-Hydroxycholesterol NA NA NA NA NA NA
Abbreviations: DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone-SO4; NA, not applicable since values of steroid metabolite was below limits
of detectability of the assay; NC, negative control; PMDD, premenstrual dysphoric disorder. The unit of measurement for all steroid metabolites is pg ml− 1.
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abnormalities of neurosteroid production do not contribute to the
pathophysiology of PMDD. Thus, our data confirm, under
controlled conditions, the absence of metabolic differences in
the formation of 5-alpha-reduced (and 3-beta-hydroxy steroid
dehydrogenated) metabolites of P4 in PMDD compared with
controls. The neurosteroid hypothesis for PMDD has been very
attractive but has been inadequately tested, to date, for the
following two reasons: (1) the actions are largely determined by
the integrated neurosteroid signal from the profile of metabolites,
which, until now, have not been accessible for measure; and (2)
samples of women with PMDD are heterogeneous with respect to
the critical variable—hormone sensitivity. Both of these obstacles
have been overcome in the current study, thus enabling us to
answer, albeit negatively, a critical etiological question (and one
that is all the more important to address, given recent
demonstration of the efficacy of a neurosteroid in another
reproductive endocrine-related mood disorder, postpartum
depression (PPD;52,53 despite the lack of evidence of abnormal
levels of allopregnanolone in PPD). Nonetheless, our findings of
otherwise normal P4-derived neurosteroid levels in PMDD are
consistent with recent evidence that the luteal-phase increase
(that is, change) in neurosteroid levels—not basal levels—
mediates the onset of symptoms in women with PMDD,23 as
blockade of 5-alpha reductase activity mitigated the PMDD
symptom onset. Finally, it is possible that our inability to
demonstrate abnormalities of neurosteroid levels or profiles may
reflect our selection of a distinct, homogeneous subphenotype—
women with documented ovarian hormone-induced behavioral
sensitivity—and therefore may not generalize to the larger and
more heterogeneous population of women with PMDD.
Our findings suggest that after a short-term exposure, women
with PMDD process ovarian steroids differently from control
women. Specifically, women with PMDD had relatively lower
serum levels of the sulfated metabolites of the neurosteroids
DHEA, pregnenolone and estradiol after exposures to either E2 or
P4. Sulfation of hydrophobic steroids reduces steroid binding to its
receptor and facilitates the transfer of the steroid from the tissues
Table 4. Changes in steroid metabolites during ovarian steroid
replacement of E2
Metabolite Median Δ P-value Q-value
PMDD NC PMDD NC PMDD NC
Estrone-SO4 888 1425 0.002 1.22E− 04 0.042 0.001
Estradiol 72 61 0.005 0.002 0.056 0.014
Estrone − 73 0 0.012 0.561 0.065# 0.978
DHEAS − 119 657 49 563 0.012 0.720 0.065# 0.978
3b-Hydroxy-
5-pregnen-
20-one-3-SO4
− 6176 959 0.018 0.847 0.076# 0.978
DHEA − 324 311 0.028 0.890 0.098# 0.978
Estradiol-3-
SO4*
47 140 0.055 6.10E− 05 0.166 0.001
Abbreviations: DHEA, dehydroepiandrosterone; DHEAS,
dehydroepiandrosterone-SO4; E2, estradiol; Median Δ, median change;
NC, normal control; PMDD, premenstrual dysphoric disorder. The unit of
measurement for all steroid metabolites is pg ml− 1. This table shows the
significant changes in steroid levels in women with PMDD and controls
with E2 addback relative to Lupron. Significant differences indicated by
Qo0.2. Only estradiol-3-SO4 levels showed significant between-group
differences following E2 treatment (*P= 0.002; q= 0.035), with a signifi-
cantly more blunted response to E2 in PMDD compared with control
women. Direct comparisons of other E2-related changes in steroid levels
between PMDD and control women did not reach significance. Within
diagnostic groups, we observed significant effects of hormone condition in
the magnitude of the change in steroid metabolite levels from Lupron to
E2 in PMDD but not controls, as follows: women with PMDD showed
significant decreases in serum levels of estrone (median Δ: PMDD= -
− 73 pg ml− 1 (decreased), #q= 0.065; controls= 0 pg ml− 1, q= 0.978),
pregnenolone sulfate (3b-hydroxy-5-pregnen-20-one-3-SO4; median Δ:
PMDD=− 6176 pg ml− 1 (decreased), #q= 0.076; controls= 959 pg ml− 1,
q= 0.978), DHEAS (median Δ: PMDD=− 119 657 pg ml− 1 (decreased),
#q= 0.065; controls= 49 563 pg ml− 1, q= 0.978) and DHEA (median Δ:
PMDD=− 324pg ml− 1, #q= 0.098 (decreased); controls= 311 pg ml− 1,
q= 0.978).
Table 5. Changes in steroid metabolites during ovarian steroid replacement of P4
Metabolite Median Δ P-value Q-value
PMDD NC PMDD NC PMDD NC
Progesterone 7850 8530 6.10E− 05 6.10E− 05 0.001 0.001
3a-Hydroxy-5a-pregnan-20-one 344 318 1.22E− 04 6.10E− 05 0.001 0.001
Pregnanediol 342 506 0.010 0.005 0.077 0.030
DHEAS* − 91 935 159 968 0.018 0.048 0.104 0.157
Cortexone 31 31 0.026 0.041 0.118 0.157
2-Hydroxyestrone − 5.4 − 10.7 0.060 0.135 0.183# 0.387
Estradiol-3-SO4 − 26 − 12 0.064 0.649 0.183
# 0.727
Cortexolone 69 0 0.064 0.727 0.183# 0.727
Androstenedione − 101 123 0.252 0.035 0.447 0.157#
17a,20a-Dihydroxyprogesterone 13 40 0.599 0.002 0.726 0.015#
Abbreviations: DHEA, dehydroepiandrosterone; Median Δ, median change; NC, normal control; P4, progesterone; PMDD, premenstrual dysphoric disorder. The
unit of measurement for all steroid metabolites is pg ml− 1. This table shows the significant changes in steroid levels in women with PMDD and controls with
P4 addback relative to Lupron. Significant differences indicated by Qo0.2. Only DHEAS levels showed significant between-group differences following P4
treatment (*P= 0.003; q= 0.073), decreasing in women with PMDD treated with P4 but increasing in control women subjected to the same hormonal
treatment. Direct comparisons of other P4-related changes in steroid levels between PMDD and control women did not reach significance. Within diagnostic
groups, we observed trend effects of hormone condition in the magnitude of the change in steroid metabolite levels from Lupron to P4 in PMDD but not
controls, as follows: 2-hydroxyestrone (median Δ: PMDD=− 5.4 pg ml−1 (decreased), #q= 0.183; controls=− 10.7 pg ml− 1, q= 0.387), estradiol-3-SO4 (median
Δ: PMDD=− 26 pg ml−1 (decreased), #q= 0.183; controls=− 12 pg ml− 1, q= 0.727) and cortexolone (median Δ: PMDD= 69 pg ml− 1, #q= 0.183;
controls= 0 pg ml− 1, q= 0.727). In addition, we also observed significant effects of hormone condition in the magnitude of the change in steroid
metabolite levels from Lupron to P4 in controls but not in PMDD, as follows: 17a, 20a-dihydroxyprogesterone (median Δ: PMDD= 13 pg ml− 1, q= 0.726;
controls= 40 pg ml− 1, #q= 0.015) and androstenedione (median Δ: PMDD=− 101 pg ml− 1 (decreased), q= 0.447; controls= 123 pg ml−1, #q= 0.157).
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into the circulation (in favor of excretion).54 The relative balance of
sulfated and non-sulfated neurosteroid metabolites determines
the actions of these compounds at excitatory and inhibitory
neuronal systems. Thus, the reduction in sulfated metabolites
observed in PMDD could contribute to the development of PMDD
symptoms, and, therefore, reflect the presence of a differential
processing of the steroid signal. Nonetheless, decreased levels of
sulfated neurosteroids would be predicted to reduce glutamater-
gic activity, promote GABA agonism and, therefore, favor
anxiolytic effects instead of the symptom provocation that occurs
in the women with PMDD during the addback phase of the study.
The decreased peripheral levels of sulfated neurosteroids in
PMDD occurred in the absence of detectable differences in the
non-sulfated forms of these same steroids (that is, estradiol, DHEA
and pregnenolone). These differences also are not explained by
differential hormone exposure as no diagnosis or diagnosis-by-
hormone condition effects were observed in peripheral levels of
E2/P4, and there were no differences in sulfated steroids during
Lupron alone.
The relative balance between sulfated and non-sulfated steroids
is maintained by two families of enzymes, the sulfotransferases
(SULT) and sulfatases (STS) working in concert with sulfate group
donor molecules, 3’-phospho-adenosine-5’-phosphosulfate (PAPS)
and its synthetic enzyme PAPS-synthase, as well as organic anion
transporter proteins that control influx and efflux into and out of
the cell, respectively.54,55 In humans, both abnormalities in the
regulation of this system and mutations of enzymes and
transporter-protein genes are associated with disease states
including behavioral conditions such as autism and attention-
deficit disorder.54 The presence of lower E2-3-sulfate in PMDD
suggests an abnormality within the SULT family of enzymes, as in
humans E2-3-sulfate is not a substrate for STS (see http://www.
genome.jp/kegg/pathway.html#metabolism (humans)). Similarly,
the absence of diagnostic differences in either estrone or its
sulfated metabolite suggests that the potential abnormality in the
regulation of sulfation is not uniformly present in PMDD.
The regulatory complexity of steroid sulfation prevents a more
precise localization of the source for the diagnostic differences
observed in this study. Members of the SULT family are
differentially localized within the brain, regulated by a wide range
of nuclear receptors and steroids (for example, by P4 and
therefore could show increased SULT activity in the luteal phase
of the menstrual cycle56), and exhibit substrate-induced feedback
inhibition.54 Although there was no clear evidence of an effect of
progesterone in this study, the difference in DHEAS levels after P4
addback (that is, decreasing in PMDD and increasing in control
women) might reflect differential processing of P4. Alternatively,
P4-induced changes in SULT could have been obscured by
changes in STS. Nonetheless, the current data seem to contradict
any significant luteal phase effect directly related to P4.
Abnormalities of both DHEAS and pregnenolone sulfate have
been suggested to contribute to abnormal affective states,45,57,58
and, therefore, it is possible that the altered profile of sulfated
neurosteroids relative to controls directly contributed to PMDD
symptom recurrence. Few studies have evaluated blood levels of
sulfated DHEA, E2 and pregnenolone during the luteal phase in
women with PMDD and controls. One study17 reported no
significant differences in pregnenolone sulfate levels between
women with PMDD and controls, and, in contrast to our findings,
higher plasma levels of pregnenolone sulfate were associated with
more severe symptoms in PMDD. Similarly, although DHEAS may
have potent affective state altering effects in women, no study has
observed significant diagnostic differences in DHEAS in women
with PMDD. Alternatively, as sulfation is regulated by both
estrogen and progesterone receptors (and their cognate ligands),
and women with PMDD exhibit altered luteal-phase responsivity
to E2/P4 in a range of phenomena,5,59–62 the differences in
sulfated metabolites could reflect further evidence of abnormal
steroid signaling in PMDD that is not directly causing symptoms.
Finally, as glucocorticoids and other stress-related factors (that is,
soluble cytokines) can regulate steroid sulfation,54 it is possible
that the altered levels of sulfated steroids occur secondary to the
effects of stress or the presence of a negative affective state in
women with PMDD during E2/P4 addback.
Several limitations in this study deserve mention. It comprised a
small sample, so that metabolite analysis did not predict which
women with PMDD were progesterone responders (that is
emergence of PMDD symptoms on progesterone) versus estrogen
responders, or precisely localize sulfation pathway abnormalities
in PMDD. Our selection criterion excluded over 50% of metabo-
lites with low levels, thus limiting the number of analyses. The
main goal of this study was to examine the potential differences in
the metabolic processing of standardized doses of ovarian
steroids in women with PMDD and controls. Although potential
confounding factors (for example, age, race, parity and BMI) were
not a concern for testing metabolite changes within diagnostic
groups, because of the paired study design, this was not the case
for testing metabolite changes between PMDD and control
groups. For these tests, the small sample size did not allow for
adequate statistical control for age, race and BMI, and additional
research is needed to determine the impact of these factors on
metabolite levels in women with PMDD. Women with PMDD and
control women did not significantly differ in either racial
distribution or parity. Levels of sulfated steroids can decline with
age; however, the role of declining age on SULT activity remains
unclear with one study describing age-related changes in
SULT2A1 expression,54 although others report no changes with
age.46,54,63,64 Similarly, few studies have documented an effect of
age on 5-alpha-reductase activity.65 Thus, it is unlikely, albeit,
possible that the 6-year difference in age between the two groups
underlies their differences in E2/P4-induced sulfated steroid levels.
Similarly, evidence in humans suggests that at least SULT1E1 is
pro-adipogenic, and, therefore, the higher average BMI observed
in the women with PMDD would be consistent with increased (not
decreased) sulfotransferase activity.54,66 The sample size also
limited our ability to examine whether race and ethnicity or parity
contributed to the observed differences in hormone levels.
Although women with PMDD and controls did not significantly
differ in these characteristics, nonetheless, we should include the
caveat that the literature does not allow one to conclude that
these factors (age, BMI, race and parity) in women significantly
regulate the synthetic enzymes relevant to our findings; that is,
STS and SULT (differential effects) and 5-alpha reductase (no
differential effects). In addition, the design of this study was
deliberately constructed to use the GnRH agonist-induced ovarian
suppression to create a hormonally uniform hypogonadal 'base-
line', a controlled condition permitting better assessment of the
effects of a physiologically relevant and standardized ovarian
steroid challenge. Our data suggest but do not definitively
demonstrate that these inferred alterations in sulfation enzymes
are relevant to the onset of PMDD symptoms during the luteal
phase of the menstrual cycle when levels of estradiol and
progesterone increase. Clearly, these pilot data need to be
followed-up in the naturalistic setting during the course of the
normal menstrual cycle in a sufficiently large sample of women to
control for differences in substrate (that is, estradiol and
progesterone secretion) as well as more specific evaluations of
SULT and STS enzyme activities. A more comprehensive assess-
ment of those steroid metabolites in which very low levels of
several metabolites could not be reliably measured (as the levels
were below the limits of detection for the steroid assays employed
in this study) is also necessary to pursue these potential
diagnostic-related differences in steroid metabolism. Finally, the
generalization of our findings to the larger population of women
with PMDD is limited by the strict research criteria employed.
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This is the first study, to our knowledge, to employ a
pharmacometabolomics approach to investigate the pattern of
both basal and stimulated levels of steroid metabolites in women
with well-characterized PMDD and controls. Notably, the same
dose of P4 was not metabolized into P4-derived neurosteroids
differently in PMDD and control women. However, we found
differences in the sulfation of estradiol, DHEA and pregnenolone
in women with PMDD when exposed to either E2 or P4,
suggesting that differences in the metabolism of sulfated
neurosteroids could be a source of the observed differential
steroid sensitivity in PMDD, and, therefore, could contribute to the
underlying pathophysiology of this condition.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGMENTS
We would like to thank Karla Thompson and Linda Schenkel of NIMH for their clinical
support and data management. This work was written as part of Peter J Schmidt’s
official duties as a Government employee. The views expressed in this article do not
necessarily represent the views of the NIMH, NIH, HHS or the United States
Government. This research was supported by the Intramural Research Program of the
NIMH, NIH. NIMH Protocols NCT00001259 and NCT00001322; Project # MH002865.
REFERENCES
1 American Psychiatric Association Diagnostic and Statistical Manual of Mental Dis-
orders. 5th edn. American Psychiatric Association Press: Arlington, VA, 2013.
2 Yonkers KA, O'Brien PMS, Eriksson E. Premenstrual syndrome. Lancet 2008; 371:
1200–1210.
3 Epperson CN, Steiner M, Hartlage SA, Eriksson E, Schmidt PJ, Jones I et al. Pre-
menstrual dysphoric disorder: evidence for a new category for DSM-5. Am J
Psychiatry 2012; 169: 465–475.
4 Schiller CE, Johnson AL, Abate AC, Rubinow DR, Schmidt PJ. Reproductive steroid
regulation of mood and behavior. Compr Physiol 2016; 6: 1135–1160.
5 Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential
behavioral effects of gonadal steroids in women with and in those without pre-
menstrual syndrome. N Engl J Med 1998; 338: 209–216.
6 Protopopescu X, Pan H, Altemus M, Tuescher O, Polanecsky M, McEwen B et al.
Orbitofrontal cortex activity related to emotional processing changes across the
menstrual cycle. Proc Natl Acad Sci USA 2005; 102: 16060–16065.
7 Protopopescu X, Butler T, Pan H, Root J, Altemus M, Polanecsky M et al. Hippo-
campal structural changes across the menstrual cycle. Hippocampus 2008; 18:
985–988.
8 Protopopescu X, Tuescher O, Pan H, Epstein J, Root J, Chang L et al. Toward a
functional neuroanatomy of premenstrual dysphoric disorder. J Affective Disord
2007; 108: 87–94.
9 Baller EB, Wei SM, Kohn P, Rubinow DR, Alarcon G, Schmidt PJ et al. Abnormalities
of dorsolateral prefrontal function in women with premenstrual dysphoric dis-
order: a multimodal neuroimaging study. Am J Psychiatry 2013; 170: 305–314.
10 Andreano JM, Cahill L. Menstrual cycle modulation of medial temporal activity
evoked by negative emotion. Neuroimage 2010; 53: 1286–1293.
11 Goldstein JM, Jerram M, Abbs B, Whitfield-Gabrieli S, Makris N. Sex differences
in stress response circuitry activation dependent on female hormonal cycle.
J Neurosci 2010; 30: 431–438.
12 Gingnell M, Bannbers E, Wikstrom J, Fredrikson M, Sundstrom-Poromaa I. Pre-
menstrual dysphoric disorder and prefrontal reactivity during anticipation of
emotional stimuli. Eur Neuropsychopharmacol 2013; 23: 1474–1483.
13 Sundstrom PI, Gingnell M. Menstrual cycle influence on cognitive function and
emotion processing-from a reproductive perspective. Front Neurosci 2014; 8: 380.
14 Dreher J, Schmidt PJ, Kohn P, Furman D, Rubinow D, Berman KF. Menstrual cycle
phase modulates reward-related neural function in women. Proc Natl Acad Sci
USA 2007; 104: 2465–2470.
15 Berman KF, Schmidt PJ, Rubinow DR, Danaceau MA, Van Horn JD, Esposito G et al.
Modulation of cognition-specific cortical activity by gonadal steroids: a positron-
emission tomography study in women. Proc Natl Acad Sci USA 1997; 94:
8836–8841.
16 Schiller CE, Schmidt PJ, Rubinow DR. Allopregnanolone as a mediator of affective
switching in reproductive mood disorders. Psychopharmacology 2014; 231:
3557–3567.
17 Wang M, Seippel L, Purdy RH, Bäckström T. Relationship between symptom
severity and steroid variation in women with premenstrual syndrome: study on
serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and
3α-hydroxy-5α-pregnan-20-one. J Clin Endocrinol Metab 1996; 81: 1076–1082.
18 Schmidt PJ, Purdy RH, Moore PH Jr., Paul SM, Rubinow DR. Circulating levels of
anxiolytic steroids in the luteal phase in women with premenstrual syndrome and
in control subjects. J Clin Endocrinol Metab 1994; 79: 1256–1260.
19 Rapkin AJ, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB. Progesterone
metabolite allopregnanolone in women with premenstrual syndrome. Obstet
Gynecol 1997; 90: 709–714.
20 Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W et al. Cortical
γ-aminobutyric acid levels across the menstrual cycle in healthy women and
those with premenstrual dysphoric disorder: a proton magnetic resonance
spectroscopy study. Arch Gen Psychiatry 2002; 59: 851–858.
21 Monteleone P, Luisi S, Tonetti A, Bernardi F, Genazzani AD, Luisi M et al. Allo-
pregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000;
142: 269–273.
22 Lombardi I, Luisi S, Quirici B, Monteleone P, Bernardi F, Liut M et al. Adrenal
response to adrenocorticotropic hormone stimulation in patients with pre-
menstrual syndrome. Gynecol Endocrinol 2004; 18: 79–87.
23 Martinez PE, Rubinow DR, Nieman LK, Koziol DE, Morrow AL, Schiller CE et al.
5alpha-Reductase inhibition prevents the luteal phase increase in plasma allo-
pregnanolone levels and mitigates symptoms in women with premenstrual
dysphoric disorder. Neuropsychopharmacology 2016; 4: 1093–1102.
24 Keefe CC, Goldman MM, Zhang K, Clarke N, Reitz RE, Welt CK. Simultaneous
measurement of thirteen steroid hormones in women with polycystic ovary
syndrome and control women using liquid chromatography-tandem mass
spectrometry. PLoS ONE 2014; 9: e93805.
25 Munzker J, Hofer D, Trummer C, Ulbing M, Harger A, Pieber T et al. Testosterone to
dihydrotestosterone ratio as a new biomarker for an adverse metabolic pheno-
type in the polycystic ovary syndrome. J Clin Endocrinol Metab 2015; 100:
653–660.
26 Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and
castration-resistant prostate cancer. Pharmacol Ther 2013; 140: 223–238.
27 Gaikwad NW. Ultra performance liquid chromatography-tandem mass spectro-
metry method for profiling of steroid metabolome in human tissue. Anal Chem
2013; 85: 4951–4960.
28 Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to
the study of central nervous system diseases. Neuropsychopharmacology 2009; 34:
173–186.
29 Sas KM, Karnovsky A, Michailidis G, Pennathur S. Metabolomics and diabetes:
analytical and computational approaches. Diabetes 2015; 64: 718–732.
30 Bicikova M, Hill M, Ripova D, Mohr P, Hampl R. Determination of steroid meta-
bolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid
Biochem Mol Biol 2013; 133: 77–83.
31 Kaddurah-Daouk R, Weinshilboum R. Metabolomic signatures for drug response
phenotypes: pharmacometabolomics enables precision medicine. Clin Pharmacol
Ther 2015; 98: 71–75.
32 Kaddurah-Daouk R, Weinshilboum RM. Pharmacometabolomics: implications for
clinical pharmacology and systems pharmacology. Clin Pharmacol Ther 2014; 95:
154–167.
33 Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV et al. TSPAN5,
ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder:
pharmacometabolomics-informed pharmacogenomics. Mol Psychiatry 2016; 21:
1717–1725.
34 Kaddurah-Daouk R, Bogdanov MB, Wikoff WR, Zhu H, Boyle SH, Churchill E et al.
Pharmacometabolomic mapping of early biochemical changes induced by ser-
traline and placebo. Transl Psychiatry 2013; 3: e223.
35 Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, Batzler A et al. Merging pharmacome-
tabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide
polymorphism imputation: selective serotonin reuptake inhibitor response
pharmacogenomics. Pharmacogenet Genomics 2012; 22: 247–253.
36 American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders. 4th edn, American Psychiatric Association: Washington, DC,
USA, 1994.
37 Rubinow DR, Roy-Byrne PP, Hoban MC, Gold PW, Post RM. Prospective assessment
of menstrually related mood disorders. Am J Psychiatry 1984; 141: 684–686.
38 Endicott J, Nee J, Cohen J, Halbreich U. Premenstrual changes: patterns and
correlates of daily ratings. J Affect Disord 1986; 10: 127–135.
39 First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for
DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-IP). Biometrics
Research, New York State Psychiatric Institute: New York, NY, USA, 2002.
40 Halbreich U, Backstrom T, Eriksson E, O'Brien S, Calil H, Ceskova E et al. Clinical
diagnosis criteria for premenstrual syndrome and guidelines for their quantifi-
cation for research studies. Gynecol Endocrinol 2007; 23: 123–130.
The steroid metabolome in women with PMDD
TV Nguyen et al
8
Translational Psychiatry (2017), 1 – 9
41 Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dys-
phoric disorder - clinical procedures and research perspectives. Gynecol Endocri-
nol 2004; 19: 320–334.
42 Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrome: the develop-
ment of research diagnostic criteria and new rating scales. Acta Psychiatr Scand
1980; 62: 177–190.
43 Park-Chung M, Malayev A, Purdy RH, Gibbs TT, Farb DH. Sulfated and unsulfated
steroids modulate γ-aminobutyric acidA receptor function through distinct sites.
Brain Res 1999; 830: 72–87.
44 Carver CM, Reddy DS. Neurosteroid interactions with synaptic and extrasynaptic
GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition,
and neuronal network excitability. Psychopharmacology 2013; 230: 151–188.
45 Vallee M. Neurosteroids and potential therapeutics: focus on pregnenolone.
J Steroid Biochem Mol Biol 2015; 160: 78–87.
46 Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of
human steroidogenesis and its disorders. Endocr Rev 2011; 32: 81–151.
47 Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349:
776–788.
48 Kugler KG, Hackl WO, Mueller LA, Fiegl H, Graber A, Pfeiffer RM. The impact of
sample storage time on estimates of association in biomarker discovery studies.
J Clin Bioinformatics 2011; 1: 1–8.
49 Bolelli G, Muti P, Micheli A, Sciajno R, Franceschetti F, Krogh V et al. Validity for
epidemiological studies of long-term cryoconservation of steroid and protein
hormones in serum and plasma. Cancer Epidemiol Biomarkers Prev 1995; 4:
509–513.
50 Reiner-Benaim A. FDR control by the BH procedure for two-sided correlated
tests with implications to gene expression data analysis. Biom J 2007; 49:
107–126.
51 Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl
Acad Sci USA 2003; 100: 9440–9445.
52 Kanes SJM, Colquhoun HM, Doherty JP, Raines SM, Hoffman EB, Rubinow DR et al.
Open-label, proof-of-concept study of SAGE-547 (allopregnanolone) in the
treatment of severe postpartum depression. Hum Psychopharmacol Clin Exp 2017;
32: 1–6.
53 Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A et al.
Brexanolone in postpartum depression: a randomized controlled trial. Lancet
2017; pii: S0140-6736(17)31264-3.
54 Mueller JW, Cilligan LC, Ilkowiak J, Arlt W, Foster PA. The regulation of steroid
action by sulfation and desulfation. Endocr Rev 2015; 36: 526–563.
55 Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL et al.
Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 2006;
90: 5–22.
56 Koizumi M, Momoeda M, Hiroi H, Hosokawa Y, Tsutsumi R, Osuga Y et al.
Expression and regulation of cholesterol sulfotransferase (SULT2B1b) in human
endometrium. Fertil Steril 2010; 93: 1538–1544.
57 Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and
neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate
(DHEAS). Front Neuroendocrinol 2009; 30: 65–91.
58 Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic
potentials. Prog Brain Res 2010; 186: 113–137.
59 Roca CA, Schmidt PJ, Altemus M, Deuster P, Danaceau MA, Putnam K et al. Dif-
ferential menstrual cycle regulation of hypothalamic-pituitary-adrenal axis in
women with premenstrual syndrome and controls. J Clin Endocrinol Metab 2003;
88: 3057–3063.
60 Rubinow DR, Smith MJ, Schenkel LA, Schmidt PJ, Dancer K. Facial emotion dis-
crimination across the menstrual cycle in women with premenstrual dysphoric
disorder (PMDD) and controls. J Affect Disord 2007; 104: 34–44.
61 Kask K, Gulinello M, Backstrom T, Geyer MA, Sundstrom-Poromaa I. Patients with
premenstrual dysphoric disorder have increased startle response across both
cycle phases and lower levels of prepulse inhibition during the late luteal phase
of the menstrual cycle. Neuropsychopharmacology 2008; 33: 2283–2290.
62 Epperson CN, Pittman B, Czarkowski KA, Stiklus S, Krystal JH, Grillon C. Luteal-
phase accentuation of acoustic startle response in women with premenstrual
dysphoric disorder. Neuropsychopharmacology 2007; 32: 2190–2198.
63 Reed MJ, Purohit A, Woo LW, Newman SP, Potter BV. Steroid sulfatase: molecular
biology, regulation, and inhibition. Endocr Rev 2005; 26: 171–202.
64 Runge-Morris M, Kocarek TA, Falany CN. Regulation of the cytosolic sulfo-
transferases by nuclear receptors. Drug Metab Rev 2013; 45: 15–33.
65 Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu
Rev Biochem 1994; 63: 25–61.
66 Ihunnah CA, Wada T, Philips BJ, Ravuri SK, Gibbs RB, Kirisci L et al. Estrogen
sulfotransferase/SULT1E1 promotes human adipogenesis. Mol Cell Biol 2014; 34:
1682–1694.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2017
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp).
The steroid metabolome in women with PMDD
TV Nguyen et al
9
Translational Psychiatry (2017), 1 – 9
